Top
image credit: Unsplash

Early monoclonal antibody therapies beneficial for COVID-19, finds study

April 14, 2021

Category:

A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate coronavirus disease 2019 (COVID-19). The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19. The study is currently available on the medRxiv* preprint server.

Read More on The Medical News